Two peptides, one nickname, and a literature that lives mostly in rats.

The short version

The Wolverine blend is a research-community nickname for two synthetic peptides — BPC-157 and TB-500 — used together. Neither is approved by the U.S. FDA for any human purpose. The evidence base lives almost entirely in rodent studies, with only a handful of small human pilots for each component and none at all for the combination.

BPC-157 (15 amino acids, derived from a sequence in human gastric juice) works chiefly on blood-vessel growth and connective-tissue repair. TB-500 (a 7-amino-acid fragment of thymosin beta-4) works on the cell's internal scaffolding — specifically the actin filaments that drive cell movement and tissue remodeling. The case for combining them rests on those non-overlapping mechanisms, not on a study that tested them together.

What the research community reports — faster injury recovery, less joint pain, gut comfort — is anecdotal, not clinical evidence. Serious questions remain about long-term safety, product purity from unregulated suppliers, and a theoretical concern around the blend's pro-angiogenic activity in cancer contexts. The effects page goes deeper on what people say and what the safety literature cautions.

What this publication is

The blend exists on the internet before it exists in a journal. Forum threads, podcast asides, late-2010s message-board lore — the so-called Wolverine stack was nicknamed in those rooms, not in a clinical trial. Online Wolverine is the opposite kind of room. It reads the published research on the two component peptides — BPC-157 and TB-500 — and indexes it for anyone trying to understand what the literature actually shows, separated from what the forums claim.

What the literature shows, in one line: BPC-157 is a 15-amino-acid peptide derived from a sequence found in human gastric juice, studied in rats for tendon, ligament, muscle, and gastrointestinal repair ^[1][2][3]. TB-500 is a synthetic fragment of the 43-amino-acid endogenous peptide thymosin beta-4 (Tβ4), carrying the LKKTETQ actin-binding motif, studied for cell-migration and wound-healing effects ^[9][12]. Neither is approved by the U.S. Food and Drug Administration for any human indication, and no controlled in-vivo study has tested the combination against either peptide alone ^[18].

That last sentence is the most important one on this site.

Why "Wolverine"

The nickname is community folklore, not a brand and not a clinical designation. It seems to have attached itself to the BPC-157 + TB-500 blend because both component peptides are reported, in preclinical models, to accelerate tissue repair — and "the regenerative one" needed a shorter name to type into a search bar. The character the nickname borrows from belongs to a separate intellectual-property universe that has nothing to do with peptide research, and this publication takes no position on it. We use "the BPC-157 + TB-500 blend" or "the regenerative peptide stack" in body copy and reserve the nickname for moments where its search relevance earns it a mention.

The other word in the domain — "online" — is also doing literal work. This is a reading room online. It is not an online clinic, an online pharmacy, or an online dispensary. The /about page is explicit about what the publisher is and is not.

What the research actually reports

BPC-157 has been studied principally by the Sikiric laboratory in Zagreb across two decades. The most-cited rodent papers report that intraperitoneal BPC-157 at 10 μg/kg accelerated Achilles tendon-to-bone healing in rats with measurable improvements in load-to-failure and collagen organization, and partially offset corticosteroid-induced healing impairment ^[1]. A separate program of work reported improved medial collateral ligament healing at 90 days across intraperitoneal, topical, and oral routes ^[2]. A muscle-crush-injury study reported normalization of creatine kinase, LDH, AST, and ALT alongside reduced hematoma at 14 days ^[3]. Vascular work in rat aortic rings and human umbilical vein endothelial cells reported endothelium-dependent vasodilation and activation of the Src–Caveolin-1–eNOS signaling pathway ^[4]. The plasma half-life is reported as under 30 minutes ^[16].

Thymosin beta-4 — the parent peptide of TB-500 — has the more substantial human evidence. A randomized Phase III trial of 0.1% RGN-259 (Tβ4) ophthalmic solution for neurotrophic keratopathy reported complete corneal healing in 6 of 10 treated subjects versus 1 of 8 placebo at day 29 ^[14]. A Phase 2 dry-eye trial reported 35.1% reduction in ocular discomfort and 59.1% reduction in corneal staining at day 56 ^[15]. In cardiac models, Tβ4 has been reported to activate integrin-linked kinase, mobilize adult epicardial progenitors, and improve function after experimental myocardial infarction ^[9][10]. In a rat embolic-stroke model, Tβ4 at 6 mg/kg improved functional outcome via axonal and vascular remodeling ^[11].

What the literature does not contain is a controlled in-vivo study of the blend itself. The combination has been written about extensively online and discussed in mechanistic reviews ^[18], but the synergy claim is an extrapolation from non-overlapping mechanisms — not a measured outcome.

Where to begin

The four signposted entry points:

• /research — the literature itself, indexed and annotated. The mechanistic split between BPC-157 (angiogenesis, VEGFR2, eNOS) and TB-500 (G-actin sequestration, ILK, cell migration) is the spine of the page.
• /dosage — what the research-context doses look like in the published rodent and human ophthalmic protocols. Not a prescription. Not a how-to. A reading of what was tested.
• /faq — the twelve questions that turned up most often in the search-intent corpus, answered with citations rather than opinion.
• /references — the full citation list, with DOIs, PubMed IDs, and links to the open-access full texts where they exist.

The /about page explains the publisher, the editorial standards, and the disclaimer in more detail.